Results 151 to 160 of about 97,696 (193)

Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors.

Current pharmaceutical design, 2015
Monoamine oxidase (MAO, E.C. 1.4.3.4) is a flavin-adenine type of enzyme with two isoforms referred to MAO-A and MAO-B that function for oxidation of monoamines.
I. Orhan
semanticscholar   +1 more source

Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors.

Current Topics in Medicinal Chemistry, 2015
Cholinesterase inhibition is the only current validated target in clinics in the treatment of Alzheimer's disease (AD). Therefore, there is continuous interest in the development and discovery of novel cholinesterase inhibitory molecules.
I. Orhan, H. O. Gulcan
semanticscholar   +1 more source

Inhibitor Design for Monoamine Oxidases

Current Pharmaceutical Design, 2013
Flavin-containing monoamine oxidases (MAO A and MAO B) located on the outer membrane of mitochondria oxidise amines and generate hydrogen peroxide. Inhibitors alleviate depression by increasing neurotransmitter levels in the brain. Elevation of neurotransmitters,although an established outcome, is a delicate balance because complete lack of MAO A is ...
openaire   +3 more sources

New Inhibitor of Monoamine Oxidase

Nature, 1960
THE following is the initial report of a structurally unique monoamine oxidase inhibitor, N-benzyl-N-methyl-2-propynylamine hydrochloride (A19120). This work includes in vitro action of this inhibitor on rat liver mitochondria as well as in vivo inhibition of monoamine oxidase of mouse brain and the liver.
J. D. Taylor, Y. C. Gladish, William B. Martin, A. A. Wykes   +3 more
openaire   +3 more sources

Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.

Journal of Medicinal Chemistry, 2015
To develop novel neuroprotective agents, a library of novel arylalkenylpropargylamines was synthesized and tested for inhibitory activities against monoamine oxidases. From this, a number of highly potent and selective monoamine oxidase B inhibitors were
P. Huleatt, M. Khoo, Y. Chua, Tiong Wei Tan, Rou Shen Liew, Balázs Balogh, R. Deme, F. Gölöncsér, K. Magyar, D. Sheela, H. Ho, B. Sperlágh, P. Mátyus, C. Chai   +13 more
semanticscholar   +1 more source

Discovery of two new classes of potent monoamine oxidase-B inhibitors by tricky chemistry.

Chemical Communications, 2015
The discovery of potent and selective monoamine oxidase-B inhibitors for the management of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases is still a challenging endeavor.
F. Cagide, T. Silva, J. Reis, Alexandra Gaspar, Fernanda Borges, Ligia R. Gomes, J. N. Low   +6 more
semanticscholar   +1 more source

Monoamine Oxidase Inhibitors [PDF]

, 1969
The chemistry, biochemistry and clinical pharmacology of MAO-inhibitors has been expertly reviewed by Pletscher et al. (1960), Biel et al. (1964) and Zirkle and Kaiser (1964).
F. Th. v. Brücke, Oleh Hornykiewicz, E. B. Sigg   +2 more
openaire   +1 more source

Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.

Journal of Medicinal Chemistry, 2014
Indazole- and indole-carboxamides were discovered as highly potent, selective, competitive, and reversible inhibitors of monoamine oxidase B (MAO-B). The compounds are easily accessible by standard synthetic procedures with high overall yields.
N. Tzvetkov, Sonja Hinz, Petra Küppers, M. Gastreich, C. Müller   +4 more
semanticscholar   +1 more source

Metabolism of Monoamine Oxidase Inhibitors

Cellular and Molecular Neurobiology, 1999
1. The principal routes of metabolism of the following monoamine oxidase inhibitors (MAOIs) are described: phenelzine, tranylcypromine, pargyline, deprenyl, moclobemide, and brofaromine. 2. Acetylation of phenelzine appears to be a minor metabolic pathway.
K. F. McKenna, Liana Urichuk, Glen B. Baker, Sidney H. Kennedy   +3 more
openaire   +2 more sources

Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors.

Journal of Medicinal Chemistry, 2013
The use of selective inhibitors of monoamine oxidase A (MAO-A) and B (MAO-B) holds a therapeutic relevance in the treatment of depressive disorders and Parkinson's disease (PD), respectively.
L. Pisani, M. Barletta, R. Soto-Otero, O. Nicolotti, Estefanía Méndez-Álvarez, M. Catto, Antonellina Introcaso, A. Stefanachi, S. Cellamare, C. Altomare, A. Carotti   +10 more
semanticscholar   +1 more source